Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pospiskova, Marketa
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Recruiting	3	864	Europe, Canada, Japan, US, RoW	Dostarlimab, Placebo	GlaxoSmithKline	Neoplasms, Head and Neck	05/28	07/29
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022 Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022 Approved for recurrent or advanced endometrial cancer Dec 2021 - Dec 2021: Approved for recurrent or advanced endometrial cancer Approved for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors Aug 2021 - Aug 2021: Approved for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors Approved for recurrent or advanced 2L dMMR/MSI-H endometrial cancer Apr 2021 - Apr 2021: Approved for recurrent or advanced 2L dMMR/MSI-H endometrial cancer Approved for mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer Apr 2021 - Apr 2021: Approved for mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer Positive CHMP opinion for use as monotherapy in women with dMMR/MSI-H 2L endometrial cancer Feb 2021 - Feb 2021: Positive CHMP opinion for use as monotherapy in women with dMMR/MSI-H 2L endometrial cancer Data from the GARNET study in solid tumor at ASCO GI 2020 Jan 2021 - Jan 2021: Data from the GARNET study in solid tumor at ASCO GI 2020 Data from the GARNET study in recurrent or advanced endometrial cancer at ESMO 2020 Sep 2020 - Sep 2020: Data from the GARNET study in recurrent or advanced endometrial cancer at ESMO 2020 Data from the GARNET study in recurrent or advanced endometrial cancer Apr 2020 - Apr 2020: Data from the GARNET study in recurrent or advanced endometrial cancer Additional data from GARNET trial for advanced solid tumors Nov 2019 - Nov 2019: Additional data from GARNET trial for advanced solid tumors From GARNET trial for 2L recurrent/advanced endometrial cancer Mar 2019 - Mar 2019: From GARNET trial for 2L recurrent/advanced endometrial cancer From GARNET trial at SITC 2018 [screenshot] Nov 2018 - Nov 2018: From GARNET trial at SITC 2018 [screenshot] Additional data from GARNET trial in advanced solid tumors at SITC 2018 Nov 2018 - Nov 2018: Additional data from GARNET trial in advanced solid tumors at SITC 2018 From GARNET trial at ESMO 2018 [screenshot] Oct 2018 - Oct 2018: From GARNET trial at ESMO 2018 [screenshot] Updated data for rec or adv MSI-H endometrial cancer [GARNET] Oct 2018 - Oct 2018: Updated data for rec or adv MSI-H endometrial cancer [GARNET] From GARNET trial at AACR 2018 [screenshot] Apr 2018 - Apr 2018: From GARNET trial at AACR 2018 [screenshot] Summarized initial results Apr 2018 - Apr 2018: Summarized initial results Summarized initial results Apr 2018 - Apr 2018: Summarized initial results In solid tumors at ASCO 2017 Jun 2017 - Jun 2017: In solid tumors at ASCO 2017 More	Recruiting	1	740	Europe, Canada, US, RoW	Dostarlimab	Tesaro, Inc.	Neoplasms	05/26	10/27